Martyn E. Caplin, professor, lead clinician, Neuroendocrine Unit at the Royal Free Hospital, London, discusses the efficacy of lanreotide for the treatment of patients with neuroendocrine tumors, as shown in clinical trials such as the CLARINET study.
Martyn E. Caplin, professor, lead clinician, Neuroendocrine Unit at the Royal Free Hospital, London, discusses the efficacy of lanreotide for the treatment of patients with neuroendocrine tumors, as shown in clinical trials such as the CLARINET study.
Prior Pelvic Radiation Linked to Higher Complications After Bladder Cancer Surgery
April 30th 2025Bladder cancer patients undergoing radical cystectomy after pelvic radiotherapy showed increased risks of rectal injury, readmission, sepsis, and surgical-site infections compared with primary surgery.
Read More
Radical Prostatectomy Shows Less Genitourinary Toxicity in Localized Prostate Cancer
April 30th 2025A study of 47,387 patients found radical prostatectomy had the lowest long-term risk of severe genitourinary complications after localized prostate cancer treatment compared to combination therapies.
Read More